SCHEMBL5475990

SCHEMBL5475990

O=C(Cc1ccc(-c2ccccc2)cc1)Nc1ccc2[nH]c3c(c2c1)CCCC3NC1CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RB1 P06400 7/20 0.54
CDC42 P60953 1/20 0.52
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CDK2 P24941 2/20 0.44
CCNE1 P24864 1/20 0.44
CDK9 P50750 1/20 0.44
CDK5 Q00535 1/20 0.44
CDK5R1 Q15078 1/20 0.44
CYP2D6 P10635 1/20 0.43
CCNA2 P20248 1/20 0.43
CCNA1 P78396 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
BRD3 Q15059 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5449016 0.90 BRD3 (0.51) RB1BRD3
SCHEMBL5468005 0.90 RB1 (0.51) RB1CDC42MEN1KMT2AALDH1A1
SCHEMBL5452796 0.86 RB1 (0.56) RB1CDC42ALDH1A1CYP2D6BRD3
SCHEMBL5455563 0.84 RB1 (0.57) RB1CDC42CYP2D6NPC1RAB9A
SCHEMBL5456655 0.84 RB1 (0.56) RB1CDC42MEN1KMT2ACYP2D6
SCHEMBL5468135 0.83 RB1 (0.55) RB1CDC42MEN1KMT2ACYP2D6
SCHEMBL5451546 0.83 RB1 (0.55) RB1MEN1KMT2ACYP2D6NPC1
SCHEMBL5456637 0.82 RB1 (0.72) RB1CDC42MEN1KMT2ACYP2D6
SCHEMBL5456607 0.81 GAA (0.49) RB1MEN1KMT2ABRD3MAPT
SCHEMBL5460471 0.80 RB1 (0.58) RB1CDC42MEN1KMT2ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed
US-20070276009-A1 Compositions and Methods for Viral Inhibition CHIRON CORPORATION 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070276009-A1 Compositions and Methods for Viral Inhibition MAVS, SARS1, ZC3HAV1 RB1 1821/4885CDC42 1241/4885MEN1 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.